SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES) Files An 8-K Other Events
ITEM 8.01 Other Events

On November 17, 2016, the Agency for Healthcare Research and Quality (AHRQ), which is an agency of the Department of Health and Human Services, published a technology assessment entitled “Retinal Prosthesis in the Medicare Population.” The technology assessment provides an overview of multiple types of retinal prosthetic devices including the Argus II, and examined the available clinical evidence for each. The technology assessment concluded that some patients clearly benefit from retinal prostheses and future studies of retinal prosthesis should make an effort to report valid and reliable measures of day-to-day function and quality of life.  Further, the assessment concluded that for these patients, no other intervention exists to address their vision problems, so even small gains may be considered important for clinical and policy decision making. No assurance can be given as to what impact, if any, this report may have on Second Sight Medical Products, Inc. The report, which is dated September 30, 2016, can be accessed at the following web site: (https://www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/id103TA.pdf). The foregoing summary is qualified in its entirety by reference to that report.To date our Argus II Retinal Prosthesis System remains the only FDA approved and commercially available Retinal Prosthesis for the treatment of retinitis pigmentosa.

About SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES)

Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company’s Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina.

SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES) Recent Trading Information

SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES) closed its last trading session down -0.18 at 2.14 with 264,925 shares trading hands.